Inflammation – Learn More:

  • Acharya, N., Penukonda, S., Shcheglova, T., Hagymasi, A.T., Basu, S., and Srivastava, P.K. (2017, March 27). Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proceedings of the National Academy of Sciences of the United States, 114(19), 5005-5010. Retrieved from http://www.pnas.org/content/114/19/5005.full.
  • Adhikary, S., Li, H., Heller, J., Skarica, M., Zhang, M., Ganea, D., and Tuma, R.F. (2011). Modulation of Inflammatory Responses by a Cannabinoid-2–Selective Agonist after Spinal Cord Injury. Journal of Neurotrauma28(12), 2417–2427. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235339/.
  • Buchweitz, JP., Karmaus, PW., Williams, KJ., Harkema, JR. and Kaminski, NE. (2008, March). Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence of presence of Delta9-tetrahydrocannabinol. Journal of Leukocyte Biology, 83(3), 785-96. Retrieved from http://www.jleukbio.org/content/83/3/785.long.
  • Clayton, N., Marshall, FH., Bountra, C., and O’Shaughnessy, CT. (2002, April). CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain, 96(3), 253-60. Retrieved from http://journals.lww.com/pain/pages/articleviewer.aspx?year=2002&issue=04000&article=00005&type=abstract.
  • Craft, R.M., Kandasamy, R., and Davis, S.M. (2013, September). Sex differences in anti-allodynic, anti-hyperalgesic and anti-edema effects of Δ9-tetrahydrocannabinol in the rat. Pain, 154(9), 1709-17. Retrieved from http://journals.lww.com/pain/pages/articleviewer.aspx?year=2013&issue=09000&article=00028&type=abstract.
  • Croxford, J.L., and Yamamura, T. (2005, September). Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? Journal of Neuroimmunology, 166(1-2), 3-18. Retrieved from http://www.jni-journal.com/article/S0165-5728(05)00160-8/fulltext.
  • De Laurentiis, A., Araujo, H.A., and Rettori, V. (2014). Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation. Current Pharmaceutical Design, 20(29), 4697-706. Retrieved from http://www.eurekaselect.com/120077/article.
  • De Petrocellis, L., Melck, D., Bisogno, T., and Di Marzo, V. (2000, November). Endocannabinoids and fatty acid amides in cancer inflammation and related disorders. Chemistry and Physics of Lipids, 108(1-2), 191-209. Retrieved from http://www.sciencedirect.com/science/article/pii/S0009308400001961.
  • Fimiani, C., Liberty, T., Aquirre, AJ., Amin, I., Ali, N. and Stefano, GB. (1999, January). Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Prostaglandins & Other Lipid Mediators, 57(1), 23-34. Retrieved from http://www.sciencedirect.com/science/article/pii/S0090698098000689.
  • Fukuda, S., Kohsaka, H., Takayasu, A., Yokoyama, W., Miyabe, C., Miyabe, Y., Harigai, M., Miyasaka, N., and Nanki, T. (2014). Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskeletal Disorders15, 275. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243420/.
  • Kinsey, S.G., Mahadevan, A., Zhao, B., Sun, H., Naidu, P.S., Razdan, R.K., Selley, D.E., Imad Damaj, M., and Lichtman, A.H. (2011). The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology60(2-3), 244–251. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021987/.
  • Klein, T.W. (2005, May). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews Immunology, 5, 400-411. Retrieved from http://www.nature.com/nri/journal/v5/n5/full/nri1602.html.
  • Matthews, A.T., and Ross, M.K. (2015). Oxyradical Stress, Endocannabinoids, and Atherosclerosis. Toxics3(4), 481–498. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686160/.
  • Michalski, C.W., Maier, M., Erkan, M., Sauliunaite, D., Bergmann, F., Pacher, P., Batkai, S., Giese, N.A., Giese, T., Friess, H., and Kleeff, J. (2008). Cannabinoids Reduce Markers of Inflammation and Fibrosis in Pancreatic Stellate Cells. PLoS ONE3(2), e1701. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2253501/.
  • Panikashvili, D., Shein, N.A., Mechoulam, R., Trembovler, V, Kohen, R., Alexandrovich, A. and Shohami, E. (2006, May). The endocannabinoid 2-AG protects the blood–brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiology of Disease, 22(2), 257-264. Retrieved from http://www.sciencedirect.com/science/article/pii/S0969996105003074.
  • Parker, J., Atez, F., Rossetti, R.G., Skulas, A., Patel, R., and Zurier, R.B. (2008, May). Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatology International, 28(7), 631-5. Retrieved from http://link.springer.com/article/10.1007%2Fs00296-007-0489-0.
  • Wright, K.L., Duncan, M., and Sharkey, K.A. (2008). Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. British Journal of Pharmacology, 153(2), 263–270. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219529/.

Return to Homepage

 
 
 
 
 

Comments